REST is a novel prognostic factor and therapeutic target for medulloblastoma.
Taylor P, Fangusaro J, Rajaram V, Goldman S, Helenowski IB, MacDonald T, Hasselblatt M, Riedemann L, Laureano A, Cooper L, Gopalakrishnan V.
Taylor P, et al.
Mol Cancer Ther. 2012 Aug;11(8):1713-1723. doi: 10.1158/1535-7163.MCT-11-0990. Epub 2012 Jul 30.
Mol Cancer Ther. 2012.
PMID: 22848092
Free PMC article.